TL;DR
Researchers have identified a previously unknown epigenetic mark called lysine nicotinylation (Knic) on histone proteins, which is triggered specifically by nicotinic acid (a form of Vitamin B3). This modification reduces chromatin accessibility to silence oncogenes like PPFIA1, effectively suppressing the growth and metastasis of hepatocellular carcinoma (liver cancer) in animal models.
What Problem Does This Paper Address?
Vitamin B3 (niacin) is a staple of human nutrition and a precursor to NAD+, a molecule central to energy metabolism. However, the relationship between Vitamin B3 and cancer is surprisingly complex and often contradictory. While some studies suggest it prevents certain cancers, others indicate it might promote metastasis in different contexts.
The researchers sought to resolve this ambiguity by examining the two primary components of Vitamin B3: nicotinic acid (NA) and nicotinamide (NAM). They discovered that these two molecules behave very differently at the epigenetic level. Specifically, they investigated how metabolic byproducts of these vitamins might "mark" histones—the proteins around which DNA is wrapped—thereby changing which genes are turned on or off in cancer cells.
Methods
The study employed a multi-disciplinary approach combining metabolic tracing, advanced sequencing, and classical cancer biology:
- PTM Identification: The team used high-resolution tandem mass spectrometry (MS/MS) to identify a novel post-translational modification (PTM) they named Knic.
- Metabolic Tracing: They used stable isotope labeling (D4-labeled NA) to prove that the nicotinyl group on the histones was directly derived from NA metabolism.
- Genomic Mapping: To understand how Knic affects the genome, they used ATAC-seq (to measure chromatin accessibility) and CUT&Tag-seq (to map exactly where the Knic mark sits on the DNA).
- Enzymatic Assays: They performed in vitro assays to demonstrate that the enzyme ACSS2 is responsible for converting NA into nicotinyl-CoA, the donor molecule for the Knic mark.
- In Vivo Models: Nude mice were used for tumorigenicity and metastasis assays to observe the real-world impact of NA vs. NAM supplementation on liver cancer.
Datasets
The authors validated their findings using several high-profile public datasets and newly generated benchmarks:
- TCGA (The Cancer Genome Atlas): Used to correlate PPFIA1 mRNA expression with patient survival and clinical outcomes in hepatocellular carcinoma (HCC).
- CPTAC (Clinical Proteomic Tumor Analysis Consortium): Used to analyze protein-level correlations between metabolic enzymes (ACSS2) and oncogenes.
- JASPAR: A database used to identify the specific binding sites for the transcription factor HOXB9.
- New Sequencing Data: The study contributed new ATAC-seq and CUT&Tag-seq datasets (deposited in the GEO repository under accessions like GSE229606).
Key Insights and Ideas
- NA and NAM are not interchangeable: While both are Vitamin B3, only NA induces the Knic mark. NAM is primarily converted to NAD+, whereas a significant portion of NA is diverted toward the production of nicotinyl-CoA.
- A "Closing" Mark: Most histone acylations (like acetylation) tend to loosen chromatin, making genes easier to read. Knic is unusual because it predominantly reduces chromatin accessibility, acting as a "silencer" for specific regions of the genome.
- The ACSS2 Connection: The enzyme ACSS2, typically known for its role in acetate metabolism, was found to be a "moonlighting" enzyme capable of synthesizing nicotinyl-CoA.
- Targeting the PPFIA1-HOXB9 Axis: The researchers pinpointed a specific mechanism where Knic prevents the transcription factor HOXB9 from binding to the promoter of the oncogene PPFIA1. By blocking this interaction, NA-induced Knic halts the cellular machinery that drives cancer metastasis.
Key Results
- Discovery of 17 Knic sites: The researchers identified 17 specific lysine residues on core histones that can be nicotinylated.
- Tumor Suppression: In mouse models, NA supplementation significantly reduced tumor size and the number of lung metastatic nodules. In contrast, NAM treatment showed no such inhibitory effect and, in some cases, had the opposite result.
- Global Chromatin Changes: ATAC-seq revealed that NA treatment closed 3,065 chromatin regions while opening only 581. Many of the closed regions were associated with pathways involved in cell adhesion and tumorigenesis.
- Clinical Relevance: Analysis of patient data showed that HCC tissues have significantly lower levels of Knic compared to healthy adjacent tissue. Patients with lower Knic levels had a demonstrably worse overall survival rate.
Limitations and Future Work
The authors acknowledge several hurdles for future research:
- Detection Sensitivity: Endogenous nicotinyl-CoA levels are extremely low under physiological conditions, making them difficult to detect without high-dose NA supplementation. More sensitive chemical probes are needed.
- Site-Specific Functions: While 17 sites were identified, the specific functional contribution of individual sites (e.g., H3K27nic vs. H4K9nic) remains to be decoded.
- The "Reader" Problem: Every epigenetic mark needs a "reader" protein to recognize it and trigger a biological response. The specific readers for the Knic mark have not yet been identified.
- Microbiome Influence: Since niacin can be produced by gut microbiota, the role of the microbiome in endogenous nicotinylation is a promising but unexplored territory.
Summary updated